CA2066699C - Biomaterial based on collagen and its applications - Google Patents

Abstract

The biomaterial based on collagen comprises, intimately associated, a support or dermal substitute based on type IV
collagen and an epidermal epithelium having differentiated cells obtained by the growth of epidermal cells on said support or dermal substitute.
This biomaterial has applications in tests in vitro in toxicology, pharmacology, or cosmetology or as a protection of wounds and burns or as a cicatrisation agent.

Description

BIOMATERIAL BASED ON COLLAOEN AND ITS APPLICATIONS
The present invention relates to a biomaterial based on collagen and applications thereof.
In the last twenty years, major advances have been made in the epidermal cell culture domain. These advances have permitted the growth of an increasing number of cells (bibliographic references 1 and 2) and have provided important insight into the factors which regulate growth ana the terminal differentiation of the epidermis. Different systems have been developed permitting the modulation of both gro-~th and differentiation (2, 3, 4). In order to further study the regulation of these biological phenomena with a view to studying dermal-epidermal interactions and reconstructing a skin-like tissue, cells have been grown on more or less complex dermal substitutes (references 5 to 13). As keratinocytes poorly anchor onto the dermal substitute, the formation of the basement membrane in vitro has been the subject of many works. The only published reports on the reformation of an almost complete basement membrane by dispersed human keratinocytes grown on collagen have described long-term cultures (40-60 days) (14, 15).
Authors have reported the role of type IV collagen in the culture of keratinocytes (22, 23, 24).
Further, there has already been realized (EP-A-0,357,755) a visceral surgery patch formed of t~o intimately associated superposed layers of collagen, namely a porous layer of fibrous collagen and a film of collagen, it being i~

possible for the collagen to be ln particular of the type III + I or of the type IV.
An ob~ect of the present lnvention is to provlde a blomaterlal comprlslng dlfferentlated epldermal cells and ln partlcular a blomaterlal of thls type the structure of whlch ls substantlally close to that of the skln.
Another ob~ect of the lnventlon ls to provlde a blomaterlal of use ln pharmacology, toxlcology and cosmetology and/or for the protectlon of wounds, burns or for clcatrlzatlon.
The appllcant has found surprlslngly that a type IV
collagen matrlx permltted the culture of epldermal cells, ln partlcular keratlnocytes, by actlng as a support or dermal substltute and obtalnlng very rapldly a blomaterial the general structure of whlch is close to that of the skin with, ln partlcular, formatlon of that whlch can be llkened to a basement membrane and horny cells.
The lnventlon therefore provldes blomaterlal based on collagen characterlzed ln that lt comprlses, lntlmately assoclated, a support formlng a dermal substltute, sald support conslstlng of a layer based on type IV collagen and a multllayered dlfferentlated eplthellum obtalned by growlng epldermal cells ln vltro, harvestlng them and then culturlng them on sald support untll stratlflcatlon wlth cell dlfferentlatlon occurs.
Advantageously, the support or dermal substltute may further comprlse a sublayer of type I + III collagen ln the form of a porous network.

., The collagens employed may be cross-linked or natlve and may be an approprlate mlxture of natlve collagen and cross-llnked collagen.
The type IV collagen may be in partlcular of placenta orlgin and prepared ln accordance wlth the teachlng of patent EP-A-9,214,035.
Preferably, the epldermal cells of colonlsatlon are keratlnocytes, ln partlcular adult normal human keratlnocytes (ANHK).
The eplthellum of thls blomaterlal has ln partlcular the followlng characterlstlcs:
a) after 6 days of culture, a good reconstltutlon of the anchorage structures ln the reglon of the dermal-epldermal ~unctlon: many well-lndlvlduallzed hemldesmosomes (anchorage plate wlth tonofllaments lnserted thereln, dense sub-basal plate, anchorlng fllaments) ln a deposltlon ln the form of an even band of extracellular materlal between the surface of the type IV collagen and the plasmal membrane resembllng a lamlna densa.
b) 3 cell compartments:
- a basement cell seating, - a plurallty of lntermedlate cell seatlngs lnterconnected by desmosomes, contalnlng granules of keratohyalln for the most superflclal thereof, - a horny stratum.
The lnventlon also provldes the appllcatlon of thls blomaterial ln pharmacologlcal, toxlcologlcal or cosmetologlcal tests, ln partlcular ln the form of an ln .~

vltro evaluatlon klt.
The lnventlon further provldes the appllcatlon of thls blomaterlal ln the protectlon/clcatrlzatlon of wounds and burns.
The lnventlon wlll now be descrlbed ln more detall wlth the ald of a process for preparlng a blomaterlal accordlng to the inventlon and in vltro and ln vlvo tests.
Preparation of the collaqens The preparatlon of natlve or oxldlzed type IV
collagen ls carrled out ln accordance wlth the process descrlbed ln the patent EP-A-0,214,035.
The type I + III collagens may be prepared by any known process.
PreParation of the dermal substltute The dermal substltute comprlses lyophlllzed and oxldlzed I + III type collagens covered by a fllm of a mlxture of type IV collagen and oxldlzed type IV collagen.
To prepare the dermal substltute, a perlodlc acld solutlon (0.002 M flnal concentratlon) was added to a 10 mg/ml solutlon of type I and type III collagens ln 0.01 N
hydrochlorlc acld. The oxldlzed collagens were recovered by phosphate preclpltatlon (Na2HPO4). The preclpltate was washed several tlmes wlth phosphate buffer (Na2HPO4) and recovered by flltratlon on Nylon llnen. The product obtalned was put lnto the form of sheets lyophlllzed and compressed.
The oxldatlon lnduced by the perlodlc acld led to the A

- 4a -formatlon of a cross-llnked collagen matrlx (patent US-4,931,546).
A solutlon of oxldlzed type IV (IVox) collagen was made ~.

2~~$599 by adding periodic acid (0.02 M final concentration) to a 20 mg/ml solution of type IV collagen in 0.01 N hydrochloric acid. After 2 hours of incubation, the type IVox collagen was dialyzed against 0.01 N hydrochloric acid.
A mixture of 10 mg/ml of a type IV collagen preparation and 10 mg/ml of an oxidized type IV collagen (4:1) (IV/IVox) was laid on the surface of the type I + III collagen sponge and then dried. The sterilization of the dermal substitute was carried out by (25 kgray) gamma-irradiation.

Culture of ANHK (adult normal human keratinocytes) Human epidermal cell suspensions were prepared by standard trypsinization procedures from normal adult skin specimens removed during plastic surgery operations. The cells were grown on gamma-irradiated 3T3 feeder cell layers in accordance with H. Green's method (1).
The culture medium was DMEM (Gibco Laboratories, Grand Island, NY, USA) and HAM F12 (Gibco) (3:1) supplemented with 10~ foetal calf serum (Boehringer Mannheim, Meylan, France), -4 _9 1.8x10 M adenine, 5 ~g/ml insulin, 2x10 M

triiodothyronine, 5 ~g/ml transferrin, 0.4 ~g/ml _10 hydrocortisone, 10 M cholera toxin and 10 ng/ml epidermal growth factor, all purchased from SIGMA, USA (complete medium). At confluence, the keratinocytes were trypsinized and stored in liquid nitrogen. Circular samples of dermal substitute, 1.6 cm in diameter, were placed in 24-well-culture plates (Falcon) and pressed to make them adhere to the plastics material. Keratinocytes in suspension were 2~.t~599 directly seeded onto these samples and put in contact with a culture medium (5x10 cells/cm2 were seeded so as to attain the confluence in 4 days). Cultures were incubated at 37~C
in a 5% CO2 atmosphere and the culture medium was changed every two days. When the epidermal cell confluence was attained, the skin substitute obtained was removed for a microscopic examination or for transplantation onto mice.
Some dermal substitutes were placed, 5 days after plating, on steel grids to bring the keratinocyte culture to the air-liquid interface. The cells were then air-exposed and fed through the dermal substitute.
The upper part of the dermal substitute is a type IV/IVox collagen layer. In order to investigate the ability of the biomaterial to permit epidermal cell growth, ANHK

were cultured onto the type IV/IVox collagen layer of the same type made up in 6-well-plates so as to permit a direct microscopic observation. The cells were seeded in suspension onto the layers in a complete medium or in a serum-free medium. The serum-free medium was DMEM and HAM

F12 (1:1) (Gibco) supplemented with 0.5 ~g/ml hydrocortisone, 5 ~g/ml insulin, 3x10 M selenite (SIGMA), 5 ~ug/ml transferrin, 1 mg/ml albumine (Institut Mérieux, Lyon, France), 5 ~g/ml fibronectin (Institut Mérieux). High seeding densities: 105 , 5x10 , 3x10 cells/cm were tested in complete medium and a low seeding density, 8x10 cells/cm , in the serum-free medium.

x~ 9 Epidermal cell differentiation For histology, the samples were fixed in Bouin's fixative medium, dehydrated in alcohol and embedded in paraffin and methacrylate. Sections were stained with HES
(hematoxyline-eosine-saffron). Immunohistochemical studies were carried out either on de-paraffinized or frozen sections, by using an avidin-biotin-alkaline phosphatase or by indirect immunofluorescence.
Epidermal differentiation was investigated by using 3 monoclonal antibodies: anti-keratin KL1 (Immunotech, Marseille, France); AKH1, a monoclonal antibody to human profilaggrin/filaggrin (Biomedical Tech. Inc., Soughton, USA), and a rabbit polyclonal antibody to involucrin (Biomedical Tech.). A mouse monoclonal antibody to beta-2 microglobulin (Immunotech) was used as a marker of human class I antigen (16 and 17).
For transmission electron microscopy, samples were fixed in 1% glutaraldehyde, 0.5% paraformaldehyde, 0.1 M phosphate buffer, prefixed in 1% osmium tetroxide, dehydrated in alcohol and embedded in an epoxy medium. Ultrathin sections were observed and photographed with a JEOL 1200 EX
transmission electron microscope (18).
Transplantation to an athymic mouse The grafting technique comes from that previously described in the bibliographic reference 19. Briefly, 17 congenitally athymic mice (Swiss nu-nu, Iffa Credo, Lyon, France) (6-10 weeks old) were anaesthetized using sodium ZC~ 9 pentobarbital, and a circular graft bed, 1.5 cm in diameter, was prepared on the dorso-lateral side of each animal by delicately removing the epidermis and the dermis, leaving the vascularization tissue on the fascia.
The graft, with its edges placed under the adjacent skin of the mouse, is overlaid with a vaseline-impregnated gauze and a capsule of plastics material (for 4 mice out of 17) maintained in place by 4 cross-formed loose sutures and protected by a bandage. For 7 other mice, the capsules of plastics material are omitted and the grafts are maintained in place and protected by a compressive bandage.
Alternatively, for the 6 remaining mice, the capsules of plastics material are replaced by a silicone transplantation chamber (Renner GmbH, Darmstadt, RFA) which was placed on the graft and which is maintained in place with 9 mm clips.
After 14, 20 or 30 days, the bandage, the capsule and the gauze were removed and the grafts were surgically excised and processed for light or electron microscopy.
Study of the basement membrane The formation of the basement membrane was studied by indirect immunofluorescence on frozen sections and by transmission electron microscopy.
Antibodies to laminin (Institut Pasteur), antibodies to type IV collagen (Institut Pasteur) or mouse monoclonal antibodies to human type IV collagen (HEYL) and the serum from patients with Bullous Pemphigoid (BP) were used to detect the three cornponents of the dermal-epiderrna ~ r~ 99 junction.
RESULTS
The dermal substitute The dermal substitute is composed of a porous (pore diameter - 50 to 100 microns) fibrous type I + III collagen layer of 400 microns thick overlaid by a dense type IV/IVox collagen film of 10 to 20 microns thick.
~ 1hen overlaid with multilayered epithelium, the substitute may be easily handled without any support.

By indirect immunofluorescence, the antibody to type IV
collagen showed a thin layer on the surface of the type I + III layer and thin filaments included in the type I +
III layer, demonstrating that the type IV/IVox collagen had slightly penetrated into the type I + III layer.

In vitro ANHK growth and differentiation The ANHK rapidly attaches to the collagen, spreads, and divides to form a confluent epithelium. Confluence is obtained in 3, 4 and 5 days when 105 , 5x10 and 3x10 cells/cm are respectively seeded. In a serum-free culture medium, a seeding density of 8x10 cells/cm allows confluency in 13 days.
Using histological and electron microscopic methods, it can be seen that the differentiation of the epidermal cells occurs from day 6 to day 25 after plating. Histological examination after 14 days in culture, shows a multilayered epithelial sheet composed of a well-organized basal cell layer and several suprabasal cell layers with more flattened -- 2~ ~99 and anucleated cells. Sparse keratohyalin granules are observed in the cytoplasm of the cells beneath the anucleated cell layers. When the cultures are exposed to the air, a thick horny layer is observed. Parakeratosis is occasionally observed.
At day 6, a basal cell layer composed of small cuboidal cells with a distinct nucleus, cytoplasmic organelles, intermediate filaments and tonofilaments, may be seen by electron microscopy. This layer is overlaid with suprabasal layers of more elongated cells which contain numerous organelles and intermediate filaments but no keratohyalin granules. The stratification then increases with the age of the culture. The cell layers are closely associated with well-structured desmosomes and narrow inter-cellular spaces.

The keratohyalin granules are sparse, have a round shape and are observed in the upper-intermediate cell layers.
Thereafter, the stratification does not significantly increase but anucleated and somewhat desquamating cells may be observed.

In vivo ANHK differentiation A well-stratified epidermis is observed only when the grafts have been maintained under graft chambers of plastics or silicone material which inhibit murine epidermal cell migration. At day 14, the type I + III collagen layer of the dermal substitute starts to be infiltrated by inflammatory and fibroblast cells. At day 30, the type I + III collagen fibres are only partly present, colonized -- 2~ 9 by numerous fibroblasts and a ~ew mononuclear cells. The degradation of the type I + III collagen layer leads in a heterogeneous manner to almost intact collagen fibres in some areas or to a reorganized tissue containing sparse human collagen fibres in others. The type IV/IVox collagen layer remains substantially intact and non-infiltrated.
Thus, the type IV/IVox collagen seems resistant to degradation in these occlusive conditions. When the dermal substitute is grafted under non-occlusive conditions, its degradation is more rapid. After grafting, the epithelium develops both a granular and a horny layer within two weeks.
The grafted epidermis is not hypertrophic as commonly described when cultured epithelium or skin-substitute are grafted (20 and 21).

Two weeks after grafting, abundant keratohyalin granules in the upper viable layer and a stratum corneum with a mild orthokeratosis are observed. At day 20, the beta-2 microglobulin is expressed in the basal cell layer and only weakly in a few suprabasal layers. At day 30, the basal cell and suprabasal cell layers are strongly labelled.
At day 14, the staining obtained with the KL1 antibody was observed for all the epidermal layers. The basal cell layer starts to be partially negative on day 20. The profilaggrin/filaggrin labelling is limited to the granular layer, as observed in normal human skin. Involucrin expression is in superbasal position on day 14, 20 and 30.
Nevertheless, at day 30 and 55, in large areas this _, 2~5"J~' ~9 expression is restricted to the intermediate, upper Malpighian layers and granular layers on day 30.
Study of the dermal-epidermal junction In vitro Electronic microscopy shows numerous hemidesmosome-like structures at the junction between the type IV/IVox collagen film and the basal cells as soon as the day 6 after plating.
The dermal-epidermal junction is linear without ridges.
There is observed an intracellular electron-dense plaque along the basal cell membrane in which are inserted intermediate filaments and a subbasal dense layer.
Anchoring filaments may be distinguished. The surface of the film appears as a dense line and an electron-dense band resembling lamina densa seems to overlay it. This resembles a aermal-epidermal junction in the skin of a human foetus at an intermediate stage of development.
By immunofluorescence, the BP antigen is expressed from day 6 in culture, whereas the laminin which is not detectable at this stage may be detected from day 12. Both antigens' labelling are observed on the basal side of basal cells in the form of a discontinuous fluorescence. The immunofluorescence reaction using the antibody to type IV
collagen shows a fluorescence on the whole thickness of the type IV/IVox collagen film.

In vivo At day 30 and day 55 after transplantation, the fine structure of the basement membrane is more clearly seen than L (~ q~/

in culture in vitro since the IV/IVox type collagen appears less dense. Numerous well-differentiated hemidesmosomes and a lamina densa are distinguished. In some areas, the type IV/IVox collagen layer seems to be partly degraded by the epidermal cells. In these areas, at day 30, fibrils reminiscent of anchoring fibrils may be seen under the lamina densa. At day 55, the connective tissue beneath the lamina densa is better organised and the anchoring fibrils are well-structured. By light mlcroscopy, the dermal-epidermal junction appears slightly unaulating and, byelectron microscopy, the dermal-epidermal interLace of the basal cells form an undulating plasma membrane in its basal portion.
The suality of the epidermis obtained permits applying the material to to~.icological, pharmacological and cosmetological evaluation tests in accordance with the usual procedures employed in biopsies of the human and animal skin , . .

- 2C~ 99 B~LI~ ~P~ICAL ~ E~NCES
1. Green H., Kehinde O. & Thomas J., Proc. Natl. Acad.
Sc., USA 76 (1979) 5665 2. Boyce S. & Ham RG., J. Invest. Dermatol. 81 ~1983) 33s 3. Hennings H., Michael D., Cheng C., Steward S., Holbrook K. & Yuspa SH., Cell 19 (1980) 245 4. Asselineau D., Bernard B., Bailly C. & Darmon M.
Exp. Cell. Res. 159 (1985) 536 5. Bell E., Sher S., Hull B., Merill C., Rosen S., Chamson A., Asselineau D., Dubertret L., Coulomb B., Lapiere C., Nusgens B. & Neveux Y., J. Invest.
Dermatol. 81 (1983) 2s 6. Coulomb B., Saiag GP., Bell E., Breitburd F., Lebreton C., Heslan M. & Dubertret T., Br. J.
Dermatol. 114 (1986) 91 7. Prunieras M., Regnier M. & Woodley D., J. Invest.
Dermatol. 81 (1983) 28s 8. Regnier M., Desbas C., Bailly C. & Darmon M., In vitro 24 (1988) 625 9. Regnier M. & Darmon M., In vitro, 25 (1989) 1000 Lenoir M-C., Bernard B., Pautrat G., Darmon M. &
Shroot B., Dev. Biol. 130 (1988) 610 11. Freeman AE., Igel HJ., Herman BJ & Kleinfeld KL., In vitro 12 (1976) 352 12. Yannas IV. ~ Burke JF., J. Biomed. Mater. Res. 14 (1980) 65 13. Boyce S. & Hansbrough J., Surgery 103 (1988) 421 14. Hirone T. & Taniguchi S., Cur. Prob. Dermatol. 10 (1980) 159 15. Chamson A., Germain N., Claudy A., Perier C. &

~ ~ 2 ~J~ ~ 9 Frey J., Arch. Derm~tol. 281 (1989) 267 16. Forsum U. & Tjemlund UM., Acta Venereol (Stockh) 57 (1977) 121 17. Mauduit G., Vincent CL., Gielen V., Faure M., Demiden A. & Thivolet J., Tissue antigens 29 (1987) 18. Garrone R. & Tiollier J., dans Bienvenu, Grimaud, Laurent, Walterde, Gruyter (Eds), Marker proteins, vol. 3 1986. pp 357-361 19. Tinois E., Faure M., Kanitakis J., Ramirez-Bosca A., Nguyen C., Tardy M., Tayot JL. & Thivolet J., Epithelia 1(1987) 141 20. Faure M., Mauduit G., Schmitt D., Kanitakis J., Demidem A. & Thivolet J., Br. J. Dermatol. 116 (1987) 161 21. Ramirez-Bosca A., Tinois E., Faure M., Kanitakis J., Roche P. & Thivolet J., J. Invest. Dermatol. 91 (1988) 36 22. Murray JC., Stingl G., Kleinman HK., Martin GR. &
Katz SI., J. Cell. Biol. 80 (1979) 197 23. Kleinman HK., Murray JC., Mc Goodwin EB. & Martin GR., J. Invest. Dermatol. 71 (1978) 9 24. Woodley D., Kimberly C. & O'Keefe J., J. Invest.
Dermatol. 94 (19gO) 139.

Claims (7)

THE EMBODIMENTS OF THE INVENTION IN WHICH AN EXCLUSIVE
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:

1. Biomaterial based on collagen characterized in that it comprises, intimately associated, a support forming a dermal substitute, said support consisting of a layer based on type IV collagen and a multilayered differentiated epithelium obtained by growing epidermal cells in vitro, harvesting them and then culturing them on said support until stratificatlon with cell differentiation occurs.

2. Biomaterial according to claim 1, characterized in that the support or dermal substitute further comprises a sublayer of at least one other type of collagen.

3. Biomaterial according to claim 2, characterized in that said sublayer comprises type I and type III collagens.

4. Biomaterial according to any one of claims 1 to 3, characterized in that the epidermal cells are keratinocytes.

5. Blomaterlal according to any one of claims 1 to 4, characterized in that the collagens are native or cross-linked collagens or mixtures of native collagen and cross-linked collagen.

6. Use of the biomaterial according to any one of claims 1 to 5 in an in vivo evaluation test in toxicology, pharmacology or cosmetology.

7. Biomaterial for protecting wounds and burns or forming a cicatrisation agent, according to any one of claims 1 to 5.